Misplaced Pages

NovaBay Pharmaceuticals

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Biopharmaceutical company
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "NovaBay Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (June 2014) (Learn how and when to remove this message)
NovaBay Pharmaceuticals, Inc.
Office in Emeryville, California
Company typePublic
Traded asAMEX: NBY
Russell Microcap Index component
Founded2000
FounderRon Najafi
HeadquartersUnited States Edit this on Wikidata
Key peopleMark Sieczkarek, M.B.A., CEO and Chairman of BOD
John (“Jack”) McGovern, CFO
Tom Paulson, M.B.A., Strategic Planning
Lewis J. Stuart, M.B.A., Chief Commercial Officer (CCO)
Glenn Moro, VP, Marketing Avenova
Justin M. Hall, Esq, Senior Vice President, General Counsel
Greg Miller, Director, Strategic Sales
Websitenovabay.com

NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis

History

NovaBay Pharmaceuticals, Inc. was founded by Ron Najafi, an organic chemist who had previously worked for several pharmaceutical, chemical, and biotech companies in the U.S. Najafi became intrigued by HOCl, hypochlorous acid, an antimicrobial substance produced by White Blood Cells while investigating the chemical reaction of White Blood Cells during oxidative burst cycle. HOCl and other chlorine-containing chemicals fight invading microbes. These natural substances rapidly oxidize the cell walls of bacteria and the protein coats of viruses, rendering them inactive.

Najafi started NovaBay Pharmaceuticals in 2000 to create a stable version of HOCl. Najafi, chemistry Nobel laureate Herbert C. Brown, and Purdue University Professor Dale Margerum recruited Dr. Lu Wang to NovaBay, where she is now Director of Product Development. She was able to develop the stable version of pure hypochlorous acid, without bleach impurities, which became NovaBay's first product, NeutroPhase and cleared by the Food and Drug Administration in 2010.

The product successfully treats a variety of chronic non-healing wounds without the use of standard antibiotics. NovaBay announced two new products named CelleRx™ for Plastic Surgery and i-Lid™ Cleanser (Now Avenova) that was cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.

Corporate Governance

As of April 1, 2016, the members of the board of directors of NovaBay Pharmaceuticals were: Mark Sieczkarek, Paul E. Freiman, Paul Li, Gail Maderis, Yonghao (Carl) Ma, Todd Zavodnick, Mijia (Bob) Wu and Xiaoyan (Henry) Liu.

Products

Products on the market

Avenova (formerly known as i-Lid Cleanser) NeutroPhase CelleRx, for Plastic Surgery

Products under development

NovaBay developed a method for making a stable pure form of hypochlorous acid (HOCl), a substance produced by the immune system as an effective first defense against microbial invaders. The company calls their proprietary formulation Neutrox. The company's chemists also created a related family of compounds which the company calls Aganocides.

The company is currently developing compounds with anti-bacterial and anti-viral action. Potential applications include flesh-eating disease, problems related to in-dwelling urinary catheters, and common eye conditions. Compounds are also being developed for the veterinary market.

References

  1. "NovaBay Avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients".
  2. "Treatment of Acute Necrotizing Fasciitis Using Negative Pressure Wound Therapy and Adjunctive NeutroPhase Irrigation Under the Foam". Wounds Research. Retrieved 2019-12-11.
  3. "NNFF Names NovaBay's (NBY) NeutroPhase Its Official 'Flesh-Eating Disease' Wound Cleanser". StreetInsider.com. Retrieved 2019-12-11.
  4. "Hypochlorous Acid as a Potential Wound Care Agent Part I" (PDF).
  5. "510(k) Summary NeutroPhase® Skin and Wound Cleaner OTC" (PDF).
  6. "Hypochlorous Acid as a Potential Wound Care Agent Part II" (PDF).
  7. "NeutroPhase® in chronic non-healing wounds" (PDF).
  8. "Treatment of Acute Necrotizing Fasciitis Using Negative Pressure Wound Therapy and Adjunctive NeutroPhase Irrigation Under the Foam".
  9. "NovaBay Avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients".
  10. NovaBay’s new Advanced i-Lid Cleanser has been Cleared by the FDA for Cleaning, Removing Debris and Microbes from the Skin around the Eyes, the Eyelids and Eyelashes eyelid and lash cleansing as part of a regimen for Blepharitis."
  11. Steven E. F. Brown (February 26, 2014). "NovaBay Pharmaceuticals makes deal for flesh-eating bacteria cleanser". San Francisco Business Times. Retrieved June 19, 2014.
  12. "NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal Health". CNBC. Archived from the original on October 5, 2013.

External links

Pharmaceutical companies of the United States
Current
Former
Tax inversion
Other
Categories: